<!DOCTYPE html>
<html lang="en">
	<head>
  		<meta charset="UTF-8">
  		<title>Bio2RDF - Drugbank</title>
		<link href="images/bio2rdf.png" rel="shortcut icon" />
		<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
  		<script src="https://code.jquery.com/jquery-3.2.1.min.js"></script>
  		<script src="handlebars-v4.0.10.js"></script>
  		<!--<script src="https://cdnjs.cloudflare.com/ajax/libs/handlebars.js/4.0.10/handlebars.runtime.min.js"></script>-->
	
		<script type="application/ld+json">{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00243",
  "@type" : "Drug",
  "administrationRoute" : "oral",
  "availableStrength" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:c0d99b4b4249a3d6029d9b16731bbe6e",
    "@type" : "DrugStrength",
    "description" : "1000 mg Tablet, film coated, extended release form with oral route"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:ea689cbfb798611ccb9ad683deb68184",
    "@type" : "DrugStrength",
    "description" : "500 mg Tablet, film coated, extended release form with oral route"
  } ],
  "clinicalPharmacology" : "Ranolazine has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. It is the first new anti-anginal developed in over 20 years.",
  "cost" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:60942f3980c819b7221ccaa9a003c990",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "4.0599999427795410156",
    "drugUnit" : "Ranexa 500 mg 12 Hour tablet"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:bf6cee006bf8b67ddb70a087e66ba993",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "6.8899998664855957031",
    "drugUnit" : "Ranexa 1000 mg 12 Hour tablet"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:cb08f8e81a42255c2974f7c3559049bf",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "4.0399999618530273438",
    "drugUnit" : "Ranexa 500 mg tablet"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:9ecd7115daeb804a4a04a36786de7ca6",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "6.6300001144409179688",
    "drugUnit" : "Ranexa 1000 mg tablet"
  } ],
  "description" : "Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina. [Wikipedia]",
  "dosageForm" : "Tablet, film coated, extended release",
  "foodWarning" : "Grapefruit and grapefruit juice should be avoided throughout treatment.",
  "identifier" : "drugbank:DB00243",
  "interactingDrug" : [ "DDI between Ranolazine and Isavuconazonium - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Topotecan - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.", "DDI between Ranolazine and Atorvastatin - Ranolazine may increase the serum concentration of AtorvaSTATin.", "DDI between Ranolazine and Aripiprazole - CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.", "DDI between Nelfinavir and Ranolazine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Fosaprepitant - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Crizotinib - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Mifepristone - May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.", "DDI between Ranolazine and Afatinib - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.", "DDI between Ranolazine and Bosentan - May decrease the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Hydrocodone - CYP3A4 Inhibitors (Weak) may increase the serum concentration of Hydrocodone.", "DDI between Ranolazine and Dabigatran etexilate - P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.", "DDI between Ranolazine and Voriconazole - Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs.", "DDI between Ranolazine and prucalopride - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.", "DDI between Ranolazine and Bicalutamide - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Enzalutamide - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Saquinavir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Rifaximin - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rifaximin.", "DDI between Ranolazine and Posaconazole - Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs.", "DDI between Ranolazine and Tetracycline - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Rifampicin - Rifampin may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Aprepitant - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Fluconazole and Ranolazine - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and LULICONAZOLE - May increase the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Phenytoin - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Delavirdine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Desipramine - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Simeprevir - May increase the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Primidone - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Lomitapide - CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.", "DDI between Ranolazine and Telithromycin - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Fosphenytoin - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Ledipasvir - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ledipasvir.", "DDI between Ranolazine and Abiraterone - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Pimozide - CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.", "DDI between Ranolazine and Pazopanib - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib.", "DDI between Ranolazine and Brentuximab vedotin - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.", "DDI between Ranolazine and Itraconazole - Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine. Fluconazole and isavuconazonium considerations are addressed in separate monographs.", "DDI between Ranolazine and Rifapentine - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Siltuximab - May decrease the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Clotrimazole - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Ritonavir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Tocilizumab - May decrease the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Norfloxacin - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Colchicine - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.", "DDI between Ranolazine and Everolimus - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.", "DDI between Ranolazine and Fosamprenavir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Silodosin - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.", "DDI between Ranolazine and Phenobarbital - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Ranolazine and Boceprevir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Dabrafenib - May decrease the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Metformin - Ranolazine may increase the serum concentration of MetFORMIN.", "DDI between Indinavir and Ranolazine - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Ivacaftor - May increase the serum concentration of CYP3A4 Substrates.", "DDI between Biotin and Ranolazine - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Telaprevir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Nefazodone - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Darunavir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Diltiazem - Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Conivaptan - May increase the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Carbamazepine - CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.", "DDI between Lovastatin and Ranolazine - May enhance the myopathic (rhabdomyolysis) effect of Lovastatin. Ranolazine may increase the serum concentration of Lovastatin. Ranolazine may also enhance the distribution of lovastatin to specific cells/tissues/organs where P-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).", "DDI between Ranolazine and Lopinavir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Dasatinib - May increase the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Rivaroxaban - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.", "DDI between Ranolazine and Deferasirox - May decrease the serum concentration of CYP3A4 Substrates.", "DDI between Ranolazine and Sulfisoxazole - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Bosutinib - P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.", "DDI between Ranolazine and Cimetidine - CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Digoxin - Ranolazine may increase the serum concentration of Digoxin.", "DDI between Ranolazine and Atazanavir - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.", "DDI between Ranolazine and Simvastatin - Ranolazine may increase the serum concentration of Simvastatin.", "DDI between Ranolazine and Clarithromycin - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine." ],
  "legalStatus" : [ "Approved", "Investigational" ],
  "manufacturer" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:75cfbba29b6af16f3d50e9b7844fead8",
    "@type" : "Organization",
    "name" : "Gilead sciences inc"
  },
  "mechanismOfAction" : "The mechanism of action of ranolazine is unknown. It does not increase the rate-pressure product, a measure of myocardial work, at maximal exercise. In vitro studies suggest that ranolazine is a P-gp inhibitor. Ranolazine is believed to have its effects via altering the trans-cellular late sodium current. It is by altering the intracellular sodium level that ranolazine affects the sodium-dependent calcium channels during myocardial ischemia. Thus, ranolazine indirectly prevents the calcium overload that causes cardiac ischemia.",
  "name" : "Ranolazine",
  "nonProprietaryName" : "Ranexa",
  "sameAs" : [ "http://www.drugs.com/cdi/ranolazine.html", "http://www.drugbank.ca/drugs/DB00243", "http://www.rxlist.com/cgi/generic/ranexa.htm" ],
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00243.html"
}</script>
	</head>

	<body>
		<br/><br/>
		
		<div id="all">
	 		<div id="main" style="text-align: center;">
	 			<div style="height: 20%;">&nbsp;</div>
	 			<img alt="Drugbank" src="images/drugbank.png" />
	 			<div id="main" style="text-align: center;">
	 				<em>Bio2RDF Drugbank Data</em>
				</div>

				<br/><br/>

			</div>

			<div id="contents">
				<script type="text/javascript">

				var templateCode = "<table><tbody><tr><td class='dataframeKey'>Drug Name</td><td>{{name}}</td></tr><tr><td class='dataframeKey'>Description</td><td>{{description}}</td></tr><tr><td class='dataframeKey'>Identifier</td><td>{{schema:identifier}}</td></tr><tr><td class='dataframeKey'>Non-Proprietary Names</td><td><ul>{{#each nonProprietaryName}}<li>{{this}}</li>{{else}}{{nonProprietaryName}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Proprietary Name</td><td>{{proprietaryName}}</td></tr><tr><td class='dataframeKey'>Drug Classes</td><td><ul>{{#each drugClass}}<li>{{this}}</li>{{else}}{{drugClass}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Clinical Pharmacology</td><td>{{clinicalPharmacology}}</td></tr><tr><td class='dataframeKey'>Manufacturer</td><td>{{#with manufacturer}}{{name}}{{/with}}</td></tr><tr><td class='dataframeKey'>Mechanism of Action</td><td>{{mechanismOfAction}}</td></tr><tr><td class='dataframeKey'>Food Warning</td><td>{{foodWarning}}</td></tr><tr><td class='dataframeKey'>URL</td><td><a href='{{schema:url}}'>{{schema:url}}</a></td></tr><tr><td class='dataframeKey'>Costs</td><td>{{#if cost.length}}<ul>{{#each cost}}<li>{{#with this}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}</li>{{/each}}</ul>{{else}}{{#with cost}}{{drugUnit}} - {{costPerUnit}}{{costCurrency}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Available Strength</td><td>{{#if availableStrength.length}}<ul>{{#each availableStrength}}<li>{{this.description}}</li>{{/each}}</ul>{{else}}{{#with availableStrength}}{{description}}{{/with}}{{/if}}</td></tr><tr><td class='dataframeKey'>Dosage Forms</td><td><ul>{{#each dosageForm}}<li>{{this}}</li>{{else}}{{dosageForm}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Administration Route</td><td><ul>{{#each administrationRoute}}<li>{{this}}</li>{{else}}{{administrationRoute}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Interacting Drugs</td><td><ul>{{#each interactingDrug}}<li>{{this}}</li>{{else}}{{interactingDrug}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Legal Statuses</td><td><ul>{{#each legalStatus}}<li>{{this}}</li>{{else}}{{legalStatus}}{{/each}}</ul></td></tr><tr><td class='dataframeKey'>Same As</td><td><ul>{{#each sameAs}}<li><a href='{{this}}'>{{this}}</a></li>{{else}}<a href='{{sameAs}}'>{{sameAs}}</a>{{/each}}</ul></td></tr></tbody></table>";
				var template = Handlebars.compile(templateCode);

				$.getJSON("jsonld/DB00243.json", function(data) {
			    	document.getElementById("contents").innerHTML += template(data);
				});
		
				</script>
			</div>
		</div>
	</body>
</html>